RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
VIVA Biotech Holdings Stock

VIVA Biotech Holdings P/S 2025

VIVA Biotech Holdings P/S

3.18

Ticker

1873.HK

ISIN

KYG9390W1015

WKN

A2PH5Q

As of Aug 23, 2025, VIVA Biotech Holdings's P/S ratio stood at 3.18, a 171.79% change from the 1.17 P/S ratio recorded in the previous year.

The VIVA Biotech Holdings P/S history

VIVA Biotech Holdings Aktienanalyse

What does VIVA Biotech Holdings do?

VIVA Biotech Holdings is a Chinese company specializing in the development of pharmaceuticals. It was listed on the Hong Kong Stock Exchange in 2018 and is headquartered in Shanghai. The company started as a small start-up in 2013 but has quickly become one of the industry leaders in pharmaceutical discovery and development. VIVA Biotech Holdings' business model revolves around creating a shared ecosystem for biotechnology start-ups and their customers. The company offers a wide range of services, including target molecule identification and validation, drug candidate optimization, and speeding up the timeline for clinical trials and commercialization. One key aspect of VIVA Biotech Holdings' business model is its VIVA Accelerator programs, which support and foster promising early-stage biotechnology start-ups. These programs provide start-ups with access to state-of-the-art facilities, expert advice, and funding opportunities. The company also operates several divisions focused on the discovery and development of new pharmaceuticals. These divisions include drug candidate synthesis, screening platforms for identifying drug candidates, and structural elucidation of proteins and other molecules. A major focus of VIVA Biotech Holdings is the development of cancer treatments. The company has developed a wide range of drug candidates that specifically target and destroy cancer cells. This includes both small molecules and biological drugs. In addition to cancer research, VIVA Biotech Holdings is also involved in the discovery and development of drugs for other diseases such as inflammatory and metabolic disorders. The company works closely with its customers and partners to develop targeted treatment options. Overall, VIVA Biotech Holdings has achieved an impressive track record in drug discovery and development in recent years. The company has developed a wide range of drug candidates at various stages of clinical development that have the potential to revolutionize the treatment of cancer and other diseases. As a company, VIVA Biotech Holdings is also committed to promoting the biotechnology sector and supporting start-ups and young companies. It is an important player in the Chinese biotech industry and an emerging company in the global pharmaceutical development market. VIVA Biotech Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding VIVA Biotech Holdings's P/S Ratio

VIVA Biotech Holdings's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing VIVA Biotech Holdings's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating VIVA Biotech Holdings's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in VIVA Biotech Holdings’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about VIVA Biotech Holdings stock

What is the price-to-earnings ratio of VIVA Biotech Holdings?

The price-earnings ratio of VIVA Biotech Holdings is currently 3.18.

How has the price-earnings ratio of VIVA Biotech Holdings changed compared to last year?

The price-to-earnings ratio of VIVA Biotech Holdings has increased by 171.79% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of VIVA Biotech Holdings high compared to other companies?

Yes, the price-to-earnings ratio of VIVA Biotech Holdings is high compared to other companies.

How does an increase in the price-earnings ratio of VIVA Biotech Holdings affect the company?

An increase in the price-earnings ratio of VIVA Biotech Holdings would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of VIVA Biotech Holdings affect the company?

A decrease in the price-earnings ratio of VIVA Biotech Holdings would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of VIVA Biotech Holdings?

Some factors that influence the price-earnings ratio of VIVA Biotech Holdings are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does VIVA Biotech Holdings pay?

Over the past 12 months, VIVA Biotech Holdings paid a dividend of 0.01 CNY . This corresponds to a dividend yield of about 0.44 %. For the coming 12 months, VIVA Biotech Holdings is expected to pay a dividend of 0 CNY.

What is the dividend yield of VIVA Biotech Holdings?

The current dividend yield of VIVA Biotech Holdings is 0.44 %.

When does VIVA Biotech Holdings pay dividends?

VIVA Biotech Holdings pays a quarterly dividend. This is distributed in the months of October, July, October, July.

How secure is the dividend of VIVA Biotech Holdings?

VIVA Biotech Holdings paid dividends every year for the past 1 years.

What is the dividend of VIVA Biotech Holdings?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is VIVA Biotech Holdings located?

VIVA Biotech Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von VIVA Biotech Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of VIVA Biotech Holdings from 7/9/2021 amounting to 0.01 CNY, you needed to have the stock in your portfolio before the ex-date on 6/16/2021.

When did VIVA Biotech Holdings pay the last dividend?

The last dividend was paid out on 7/9/2021.

What was the dividend of VIVA Biotech Holdings in the year 2024?

In the year 2024, VIVA Biotech Holdings distributed 0 CNY as dividends.

In which currency does VIVA Biotech Holdings pay out the dividend?

The dividends of VIVA Biotech Holdings are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von VIVA Biotech Holdings

Our stock analysis for VIVA Biotech Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of VIVA Biotech Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.